Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

in in patients with sHF at baseline (PRADAXA 150mg: 3.10%; warfarin: 3.90%) and those without sHF (PRADAXA 150mg: 3.39%; warfarin: 3.45%).(1) There was no significant interaction for major bleeding events between the two subgroups of patients (HR = 0.79 for patients with sHF; 0.99 for patients without sHF; p-value for interaction = 0.74).(1) Additionally, annual rates of intracranial bleeding were lower with PRADAXA 150mg twice daily than warfarin in patients with sHF at baseline (PRADAXA 150mg: 0.26%; warfarin: 0.65%) and those without sHF (PRADAXA 150mg: 0.34%; warfarin: 0.80%).(1) There was no significant interaction for intracranial bleeding events between the two subgroups of patients (HR = 0.39 for patients with sHF; 0.42 for patients without sHF; p-value for interaction = 0.72).(1)

"It is important that we continue to analyze the data from RE-LY to better understand the use of PRADAXA in different types of non-valvular atrial fibrillation patients," said John Smith, MD, PhD, senior vice president for clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Boehringer Ingelheim is committed to informing physicians about the clinical implications for patients taking PRADAXA through data analyses such as these."

PRADAXA was approved by the U.S. Food and Drug Administration in October 2010 to reduce the risk of stroke and systemic embolism in patients with NVAF.(6) PRADAXA has been shown to reduce both ischemic and hemorrhagic stroke compared to warfarin in patients with NVAF.(6)  In the first eleven months after approval, more than 420,000 patients in the U.S. were prescribed PRADAXA.(7) Dabigatran is recommended in a 2011 update to atrial fibrillation treatment guidelines.

Additional RE-LY Subanalysis Presented at AHA

A second subanalysis assessed the risk of peri-operative bleeding with PRADAXA 150mg twice daily compared to warfarin in patients undergoing surgery (n = 4,615).(8) 
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Technologies Inc. , a provider of medical imaging devices and ... has received a notice from the staff of the ... to delisting after missing another opportunity to file financial reports. ... the quarter ended June 30 would serve as an additional ...
... - A new biofuels company spun out of Lucigen Corp. ... presented with the second of two state grants. , ,C5-6, ... will receive a $115,000 grant as part of the Bio-Based ... was on hand to announce the grant, which is part of ...
... Madison, Wis. - Wisconsin-based high-tech startup and ... far-flung investors. The most recent example of this ... that is developing laboratory tools for analysis of ... of protein targets, quantitative microarrays, and related products, ...
Cached Biology Technology:Madison business receives $115,000 of new state biofuels funding 2Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2
(Date:4/17/2014)... that devastate honeybees in Europe, Asia and the United ... appear to be impacting native honeybee populations at this ... invasive pests include including Nosema microsporidia and ... to be resilient to these invasive pests, which suggests ... in Europe, Asia and the United States currently are ...
(Date:4/17/2014)... warning on the possible effects of gases such as ... that of carbon dioxide. Now a team of Swiss-German ... regenerable electron acceptors which helps explain why large amount ... released to the atmosphere. However, there are worries that ... a vicious cycle to release large amounts of methane ...
(Date:4/17/2014)... of Texas Medical Branch at Galveston are the ... radiation for cervical cancer should begin colorectal cancer ... UTMB researchers, finding a high incidence of secondary ... radiation, offer new recommendations that the younger women ... eight years after their initial cervical cancer diagnosis ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... Aquaculture production of seafood will probably remain the ... according to an assessment published in the January 2009 ... S. Diana of the University of Michigan at Ann ... harmful effects of aquaculture, the technique may, when practiced ...
... Yan Liu imagine and assemble intricate structures on a ... DNA molecule, a versatile building material offering near limitless ... issue of Science , Yan and Liu, researchers ... of Chemistry and Biochemistry, reveal for the first time ...
... Hopkins neuroscientists has worked out how some newly discovered ... with the brain. The report appears online this week ... are a small number of nerve cells in the ... in the retinarods and conesmelanopsin-containing cells are not used ...
Cached Biology News:Aquaculture's growth seen as continuing 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3